Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia.
Hargarter L, Lahaye M, Cherubin P, Lambert M, Swarz M, Joldygulov G, Vischia F, Chomskaya V, Bozikas VP, Tsapakis EM, Schreiner A. Hargarter L, et al. Among authors: schreiner a. World J Biol Psychiatry. 2018;19(sup3):S147-S157. doi: 10.1080/15622975.2017.1315176. Epub 2017 Jun 8. World J Biol Psychiatry. 2018. PMID: 28594264
A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A, Bergmans P, Cherubin P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Hargarter L. Schreiner A, et al. Clin Ther. 2014 Oct 1;36(10):1372-88.e1. doi: 10.1016/j.clinthera.2014.08.014. Epub 2014 Oct 23. Clin Ther. 2014. PMID: 25444566 Free article. Clinical Trial.
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. Hargarter L, et al. Among authors: schreiner a. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:1-7. doi: 10.1016/j.pnpbp.2014.11.006. Epub 2014 Nov 15. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25448776 Free article. Clinical Trial.
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A, Cherubin P, Lahaye M, Hargarter L. Schreiner A, et al. Schizophr Res. 2015 Dec;169(1-3):393-399. doi: 10.1016/j.schres.2015.08.015. Epub 2015 Oct 1. Schizophr Res. 2015. PMID: 26431793 Free article. Clinical Trial.
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A, Caspi A, Bergmans P, Cherubin P, Keim S, Lara E, Pinchuk I, Schuepbach D, Suleman S, Hargarter L. Schreiner A, et al. Psychopharmacology (Berl). 2017 Jan;234(1):3-13. doi: 10.1007/s00213-016-4445-0. Epub 2016 Nov 5. Psychopharmacology (Berl). 2017. PMID: 27815602 Free PMC article.
Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
Schreiner A, Bergmans P, Cherubin P, Keim S, Llorca PM, Cosar B, Petralia A, Corrivetti G, Hargarter L. Schreiner A, et al. J Psychopharmacol. 2015 Aug;29(8):910-22. doi: 10.1177/0269881115586284. Epub 2015 May 21. J Psychopharmacol. 2015. PMID: 25999398 Free PMC article. Clinical Trial.
374 results